Curis (CRIS) Stock Price, News & Analysis

Curis, Inc. (NASDAQ: CRIS) is a biotechnology company in the biological product manufacturing sector that focuses on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor targeting IRAK4 and, in certain disclosures, FLT3. According to the company’s public statements, emavusertib is being advanced in multiple clinical settings for hematologic malignancies and lymphomas, with an emphasis on patients who have relapsed or are refractory to existing therapies.

Curis states that emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed or refractory primary central nervous system lymphoma (PCNSL), including in combination with the BTK inhibitor ibrutinib. It is also being studied as a monotherapy in the TakeAim Leukemia Phase 1/2 study (CA-4948-102) in patients with relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (hrMDS), and in a frontline AML triplet study (CA-4948-104) that adds emavusertib to venetoclax and azacitidine in AML patients who have achieved complete remission but remain minimal residual disease positive.

The company reports that emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML and MDS, and from the European Commission for the treatment of PCNSL. Curis also discloses that, through a 2015 collaboration with Aurigene Discovery Technologies Limited, it holds an exclusive license to emavusertib (CA-4948).

In addition to its internal development programs, Curis has described a licensing relationship under which it licensed its rights to Erivedge (vismodegib), a Hedgehog pathway inhibitor for advanced basal cell carcinoma, to Genentech, a member of the Roche Group. Genentech and Roche have been responsible for commercializing Erivedge. Curis has also reported a series of royalty-related and asset transactions involving its interest in Curis Royalty LLC and the Erivedge business, including the sale of its interest in Curis Royalty and the associated Erivedge intellectual property and license agreement to an entity managed by Oberland Capital, after which Curis stated it would no longer be entitled to revenues under that license agreement.

Curis has undertaken multiple equity and warrant financings, including registered direct offerings, private placements, and PIPE financings, as disclosed in its Form 8-K filings. These transactions have involved common stock, preferred stock, pre-funded warrants, and various series of warrants, with stated uses of proceeds that include research and development, general corporate purposes, and working capital. The company has also entered into registration rights agreements to register the resale of shares issuable upon conversion of preferred stock and exercise of warrants.

The company has disclosed Nasdaq listing compliance matters, including notices related to the market value of listed securities requirement and an exception period granted by the Nasdaq Hearings Panel to regain compliance. Curis has indicated that it is pursuing alternatives to maintain its listing on The Nasdaq Capital Market, while also noting that there can be no assurance that it will ultimately remain listed.

Curis regularly provides business updates and clinical data through press releases and conference presentations. These updates have included interim data from the frontline AML triplet study, presentations at major oncology and hematology meetings such as ASH, ASCO, the Society for Neuro-Oncology (SNO), and other conferences, and descriptions of ongoing and planned studies in PCNSL, secondary CNS lymphoma (SCNSL), CLL, AML, MDS, and pancreatic ductal adenocarcinoma in an investigator-sponsored setting.

Business focus and development strategy

Based on its public disclosures, Curis’s business is centered on clinical development of emavusertib across several indications in hematologic cancers and lymphomas. The company highlights combination approaches with BTK inhibitors in PCNSL and CLL, as well as combinations with venetoclax and azacitidine in AML, alongside monotherapy development in AML and hrMDS. Curis has communicated that it engages with clinical investigators and key opinion leaders to inform the design of potential registrational and earlier-stage studies.

Curis has also described a strategy of using collaborations and licensing to support its programs. Its collaboration with Aurigene Discovery Technologies Limited underpins its exclusive license to emavusertib. Historically, its license agreement with Genentech for Erivedge generated royalty revenues, and Curis entered into royalty monetization and subsequent sale transactions related to that stream, as detailed in its SEC filings.

Regulatory designations and collaborations

The Orphan Drug Designations granted to emavusertib for PCNSL, AML and MDS by the FDA, and for PCNSL by the European Commission, are repeatedly noted in Curis’s press releases. The company has also referenced a CRADA with the U.S. National Cancer Institute in certain forward-looking statements, and has emphasized the importance of its long-standing collaboration with Aurigene Discovery Technologies Limited for emavusertib.

Capital markets and listing disclosures

Curis’s Form 8-K filings describe capital-raising activities through offerings of common stock and warrants, and later through a PIPE financing involving Series B convertible non-redeemable preferred stock and multiple warrant series. The company has also used an at-the-market sales agreement structure, subject to applicable prospectus supplements, to sell common stock under an effective shelf registration statement.

In separate Form 8-K filings, Curis has reported Nasdaq notifications regarding non-compliance with the market value of listed securities requirement, the company’s request for a hearing before a Nasdaq panel, and an exception period granted to attempt to regain compliance. Curis has stated that its common stock remained listed and eligible for trading on Nasdaq during the appeal process, while cautioning that there is no assurance of continued listing.

Use of proceeds and financial considerations

In connection with its financings, Curis has disclosed that it intends to use net proceeds, together with existing cash and cash equivalents, to fund research and development activities, general corporate expenses, and working capital. The company has also provided estimates of its cash runway in press releases and Form 8-K disclosures, noting that these estimates depend on assumptions that may change.